Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]

MOG-Antibody Testing and the Search for Effective Treatment in MOGAD: Eoin P. Flanagan, MB, BCh

Articles

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform the fight against dementia.

AI-Powered Neurotech Could Revolutionize Dementia Care and Unlock Communications

In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.

Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments

Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.

Complement Inhibitors Ravulizumab and Eculizumab Impact Measures of Neuroaxonal Damage

The professor of neurology at Mayo Clinic talked about MOG-antibody associated disease, a relatively newly recognized demyelinating condition of the central nervous system. [WATCH TIME: 4 minutes]

Understanding MOG-Antibody Associated Disease in Clinical Research: Eoin P. Flanagan, MB, BCh

, has been with the team since September 2022. Follow her on Twitter 

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.
 

NeurologyLive® Clinician of the Month Spotlight: Kelly Papesh, DNP, APRN, FNP-BC 

, has been with the team since October 2019. Follow him on Twitter 

Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.

Expanding Access to CGRP Medications as First-Line Treatments: Thoughts and Implications

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Neurology Comic: Low-Res Memory